36p6d5: secreted tumor antigen
CA 2386858 C · Owner: Mitchell, Steve Chappell · Inventors: Raitano, Arthur B.; Afar, Daniel E. H.; Faris, Mary
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described is a gene and its encoded secreted tumor antigen termed 36P6D5, and , to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5 particularly including , cancers of the bladder kidney, prostate, breast, colon, ovary and pancreas.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 30, 2000 and granted December 20, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 30, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 30, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.